Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The Lancet, 2019 - thelancet.com
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …
被引用次数：554 相关文章

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The …, 2019 - research.ed.ac.uk
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …
[PDF] siditalia.it

[PDF][PDF] Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - 2019 - siditalia.it
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun… - The Lancet (British …, 2019 - scholarship.miami.edu
Abstract Hypoglycemic Agents-therapeutic use Double-Blind Method Humans Middle Aged
Recombinant Fusion Proteins-therapeutic use Male Albuminuria-prevention & control …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

REWIND Investigators - The Lancet, 2019 - yonsei.elsevierpure.com
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

HC Gerstein, HM Colhoun, GR Dagenais… - Lancet (London …, 2019 - europepmc.org
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …
[HTML] ucm.es

[HTML][HTML] Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais… - The …, 2019 - produccioncientifica.ucm.es
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

REWIND Investigators - The Lancet, 2019 - pure.ewha.ac.kr
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais… - The …, 2019 - researchonline.gcu.ac.uk
Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - 2019 - pubmed.ncbi.nlm.nih.gov
Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal
outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the …